Leading the Way in Life Science Technologies

GEN Exclusives

More »

April 1, Vol. 27, No. 7

  • Feature Articles

    • Company Update: GE Cultivates Its Life Sciences ...
    • Carol Potera
    • GE Healthcare , a $17-billion unit of General Electric, employs 46,000 people worldwide and is headquartered in Chalfont, St Giles, Buckinghamshire, UK GE Healthcare Life Sciences (wwwgelifesciencescom), one of six main business units of GE Healthcare, has international headquarters ... more »
    • CGH for Detecting Copy Number Variation
    • Vicki Glaser
    • High density, oligonucleotide-based array-Comparative Genomic Hybridization (aCGH) technology is improving the capability to perform genome-wide DNA copy number assessment and to zoom in for a high-resolution look at targeted regions of the genome These abilities are driving growth in the ... more »
    • Combating Ocular Disease
    • Elizabeth Lipp
    • Macular degeneration, be it wet or dry, gets a lot of airtime in a variety of healthcare forums And no wonder—at this time there is no cure, although there are treatments to stem the damage As our population ages and ... more »
    • Streamlining Biomarker Validation Activities
    • Vicki Glaser
    • Although huge numbers of candidate biomarkers have been identified, “few have been validated,” said Wayne Patton, PhD, biochemistry director at PerkinElmer’s (wwwperkinelmer com) Life & Analytical Sciences division “Meaningful validation will require high-throughput bioinformatics and large sets of data” In ... more »
  • Columns

    • New Funding Model for Start-Ups
    • Barbara Schilberg
    • Start-up life sciences companies are the lifeblood of medical innovation and an engine for economic growth They depend on funding to move from academic labs or entrepreneurial concepts to potentially life-saving treatments When it works, the interdependence of inventiveness and ... more »
    • Acceleron Takes on Bone & Muscle Repair
    • Carol Potera
    • Acceleron Pharma (wwwacceleronpharmacom) was established in 2003 to develop biotherapeutics for musculoskeletal, metabolic, and cancer-related diseases The company’s founders not only had novel insights about how to control protein families involved in tissue growth and repair, but they also ... more »